Mabwell ADC Case Report Highlights Rare Pseudoprogression Phenomenon
Event summary
- Mabwell's Nectin-4 targeting ADC, 9MW2821, is the subject of a case report published in The New England Journal of Medicine (NEJM) on April 22, 2026.
- The report details a rare instance of hepatic pseudoprogression observed in a patient with advanced cervical cancer treated with 9MW2821.
- The patient experienced initial tumor regression followed by a temporary appearance of a liver lesion, later confirmed to be inflammatory rather than cancerous.
- 9MW2821 is the first Nectin-4 ADC to enter Phase III clinical trials for cervical cancer, with enrollment completed and interim analysis expected in H2 2026.
- A Phase II combination study with toripalimab is currently underway.
The big picture
This case report highlights a previously underappreciated phenomenon in ADC therapy, challenging conventional radiographic assessment of treatment response. The observation of pseudoprogression in an ADC, typically associated with immunotherapies, suggests a complex interplay between targeted drug delivery and immune system activation. Mabwell's 9MW2821, as the first Nectin-4 ADC in Phase III, carries significant strategic weight, and the management of this unexpected side effect will be crucial for its commercial success.
What we're watching
- Clinical Adoption
- The widespread adoption of 9MW2821 will depend on how clinicians interpret and manage the potential for pseudoprogression, which could lead to premature treatment discontinuation if not recognized.
- Regulatory Scrutiny
- Regulatory agencies will likely scrutinize the management of pseudoprogression in clinical trials for ADCs, potentially impacting approval timelines and labeling requirements.
- Competitive Landscape
- The emergence of pseudoprogression as a key consideration in ADC development could influence the strategies of other companies pursuing similar therapies, potentially shifting the focus towards more nuanced biomarker assessments.
Related topics